Special Issue "Multifunctional Ligands Against Alzheimer's Disease"
Deadline for manuscript submissions: 31 October 2019
Prof. Dr. Barbara Malawska
Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
Website | E-Mail
Interests: medicinal chemistry; drug design; Alzheimer’s disease; multifunctional ligands; cholinesterase inhibitors; beta-secretase inhibitors; amyloid-beta aggregation; tau inhibitors; physicochemical properties
Over 100 years ago, Dr. Alois Alzheimer described an unknown brain disorder that today bears his name. Alzheimer’s disease is a progressive, incurable, and complex neurodegenerative disease that affected over 30 million people worldwide in 2018. The main hallmarks of the disease, found in the brains of Alzheimer’s patients, are deposits of beta-amyloid aggregates (senile plaques) that are located outside neurons, and twisted strands of protein tau (neurofibrillary tangles) that are located inside neurons. These pathological changes develop in the brain regions that are related to the memory and cognitive functions. As the cholinergic system is associated with memory and cognition, impaired cholinergic neurotransmission induces symptoms of cognitive decline and memory impairment in AD patients. Moreover, the pathogenesis of the disease includes excitotoxicity, neuroinflammation, mitochondria damage, oxidative stress, and metal ion dysregulation, which lead to a massive damage of neurons, synaptic dysfunction, neuronal death, and finally, to advanced dementia. At present, there is no available treatment that may slow down or stop the neurons’ damage and death.
As a result of the multiple factors that cause Alzheimer’s disease as well as the identification of many potential biological targets, a multi-target approach has been applied in search for potential drugs. Its goal is to create a single molecule, called a multifunctional ligand, that can interact selectively with several of the desired biological targets relevant for the disease. This strategy has been successfully developed since 2000, based on the observation that many marketed drugs are substantially promiscuous agents. The development of multifunctional ligands as potential anti-Alzheimer’s drugs has also accelerated over the recent years. This Special Issue aims to provide a forum for the presentation and dissemination of the results of the design, synthesis, and biological evaluation of novel multifunctional compounds against Alzheimer's disease. It is a very attractive topic; thus, we expect that this Special Issue will be a good platform for sharing our research results.
Prof. Dr. Barbara Malawska
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Alzheimer’s disease
- Multi-target drug discovery
- Multifunctional ligands
- Enzymes inhibitors: cholinesterase, β-secretase, and monoaminooxidase
- Neurotoxic peptide (beta amyloid, tau protein) aggregation inhibitors
- Glycogen-synthase kinase-3β inhibitors
- G-protein coupled receptors (serotoninergic, histaminergic, cannabinoid, and adenosine) ligands
- Metal chelators